ARA-290
ARA-290 (cibinetide) is an 11-amino-acid research peptide derived from the helix-B region of erythropoietin. Studied in tissue-protection and metabolic research models.
We have not published an audit on ARA-290. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
(VEGF, nitric oxide, tendon healing), gut protection, musculoskeletal repair, oral vs injectable research, 2026 FDA reclassification status, safety profile, and clinical trial evidence for this gastric-derived healing peptide. Cognitive Enhancement Brain & Neuroprotection Semax Semax peptide guide: not FDA approved, but used in Russia since 2011. Covers BDNF upregulation, stroke recovery data, int [Source: Peptide Protocol Wiki]
ARA-290 is a lab-made peptide based on part of the erythropoietin protein; it is designed to activate a protective signaling pathway in tissues and nerves (called the innate repair receptor) without stimulating red blood cell production, and researchers are studying whether this can reduce nerve damage and inflammation.
Reported side effects
No specific side effects are described in the available studies beyond a general statement that no safety concerns were reported in one small short-term trial, and that the full safety profile remains unknown due to limited and short-duration research.
Who should avoid it
The page does not list specific groups who must avoid ARA-290, but it says anyone with concerns about blood clots, cancer, immune disease, pregnancy, or breastfeeding should speak with a qualified clinician before considering it.
What gets monitored
The page mentions the following assessments used in clinical trials that could inform monitoring: corneal nerve fiber area and corneal nerve fiber density (via corneal confocal microscopy), intraepidermal nerve fiber markers, Small Fiber Neuropathy Screening List scores, Brief Pain Inventory, PainDetect scores, fatigue scales, quality-of-life measures, HbA1c, and lipid measures. These are described as study endpoints, not as a formal monitoring protocol. [Source: Peptide Dosages]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for ARA-290 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 4 mg | Once daily28 days | subcutaneous or intranasal or oral | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
- Once daily28 days
- subcutaneous or intranasal or oral
- Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).
Sources
The reference sections above are imported from our compound knowledge base, which classes the evidence for ARA-290 as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.
Peptide bioregulator referenced for pineal support.